After cardiovascular disorders, cancer is the world 's second leading cause of mortality. The location of the cancer in the bodily organ determines the type of cancer. Different forms of cancer have different metabolic behaviors that are sometimes conflicting. Nonetheless, the oncogenic phenotype is supported by each cancer's unique metabolism. The immuno-biological microenvironments at distinct metastatic organ sites are major factors for variances in efficacy, and immunotherapy benefits a small proportion of patients across multiple cancer types. Recent advancements in cancer diagnosis and treatment, cancer survival has increased, and so there is a greater emphasis on quality rather than quantity of survival.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Nanomedicine in humans: 30 years of fighting diseases
Thomas J Webster, Northeastern University, United States
Title : Diagnosis and treatment of primary cardiac lymphoma in an immunocompetent 27-year-old man
Moataz Taha Mahmoud Abdelsalam, Madinah Cardiac Center, Saudi Arabia
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Personalized and Precision Medicine (PPM) through the view of biodesign-inspired translational research: An option for clinical oncologists, caregivers, and consumers to realize the potential of genomics-informed care to secure human biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation